AF-12198
ALT-803
ANXA2
ARGX-109
ATC code L01
Abemaciclib
Acalabrutinib
Adagrasib
Adargileukin alfa
Adipotide
Afatinib
Aflibercept
Aldesleukin
Alectinib
Alemtuzumab
Alpelisib
American Society of Health-System Pharmacists
Amivantamab
Anakinra
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anrukinzumab
Anti-cancer medication
Antineoplastic
Asciminib
Atexakin alfa
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
BRAF (gene)
Baricitinib
Basiliximab
Bcr-abl fusion protein
Belantamab mafodotin
Benralizumab
Bermekimab
Bevacizumab
Binetrakin
Binimetinib
Biological half-life
Blinatumomab
Bosutinib
Boxed warning
Brazikumab
Brentuximab vedotin
Briakinumab
Brigatinib
Brodalumab
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD4
CD52
CDK inhibitor
Cabozantinib
Canakinumab
Cancer immunotherapy
Capillary leak syndrome
Capmatinib
Catumaxomab
Cediranib
Celmoleukin
Cemiplimab
Ceritinib
Cetuximab
ChEMBL
ChemSpider
Chemical formula
Cintredekin besudotox
Clazakizumab
Cobimetinib
Colony stimulating factor 1 receptor
Copanlisib
Cosibelimab
Crizotinib
Cutaneous T-cell lymphoma
Dabrafenib
Daclizumab
Dacomitinib
DailyMed
Dalpiciclib
Daniplestim
Daratumumab
Dasatinib
Denenicokin
Denileukin diftitox (data page)
Dinutuximab beta
Diphtheria toxin
Doi (identifier)
Dostarlimab
DrugBank
Drug class
Drug nomenclature
Drugs.com
Dupilumab
Durvalumab
Duvelisib
EML4
Edodekin alfa
Edrecolomab
Efavaleukin alfa
Efineptakin alfa
Elotuzumab
Elranatamab
Elsilimomab
Encorafenib
Enfortumab vedotin
Enokizumab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlotinib
Everolimus
Exotoxin
Fedratinib
Fezakinumab
Fibroblast growth factor receptor
Filgotinib
Fletikumab
Food and Drug Administration
Fruquintinib
Fusion protein
Futibatinib
Gefitinib
Gemtuzumab ozogamicin
Gevokizumab
Gilteritinib
Glasdegib
Glofitamab
Guide to Pharmacology
Guselkumab
HER2/neu
Hedgehog signaling pathway
IL17A
IL17B
IL17C
IL17D
IL17E
IL17F
IL18BP
IL22RA1
IL36A
IL36B
IL36G
IUPAC nomenclature of chemistry
Iboctadekin
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Idelalisib
Ilodecakin
Imatinib
Immunomodulator
Inavolisib
Indicated
Infigratinib
Inolimomab
Inotuzumab ozogamicin
Interferon Î»4
Interleukin-10 receptor
Interleukin-11 receptor
Interleukin-12 receptor
Interleukin-13 receptor
Interleukin-15 receptor
Interleukin-17 receptor
Interleukin-18 receptor
Interleukin-1 receptor
Interleukin-2
Interleukin-20 receptor
Interleukin-21 receptor
Interleukin-22 receptor
Interleukin-23 receptor
Interleukin-27 receptor
Interleukin-28 receptor
Interleukin-2 receptor
Interleukin-31 receptor
Interleukin-3 receptor
Interleukin-4 receptor
Interleukin-5 receptor
Interleukin-6 receptor
Interleukin-7 receptor
Interleukin-8 receptor
Interleukin 1
Interleukin 10
Interleukin 10 receptor, beta subunit
Interleukin 11
Interleukin 12
Interleukin 13
Interleukin 14
Interleukin 15
Interleukin 16
Interleukin 17
Interleukin 18
Interleukin 19
Interleukin 1 alpha
Interleukin 1 beta
Interleukin 1 receptor-like 1
Interleukin 1 receptor-like 2
Interleukin 1 receptor antagonist
Interleukin 2
Interleukin 20
Interleukin 20 receptor, alpha subunit
Interleukin 20 receptor, beta subunit
Interleukin 21
Interleukin 22
Interleukin 23
Interleukin 24
Interleukin 26
Interleukin 27
Interleukin 28
Interleukin 28A
Interleukin 28B
Interleukin 29
Interleukin 3
Interleukin 31
Interleukin 32
Interleukin 33
Interleukin 34
Interleukin 35
Interleukin 36
Interleukin 36 receptor antagonist
Interleukin 37
Interleukin 38
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 7
Interleukin 9
Interleukin 9 receptor
Interleukin receptor
Intravenous
Ipilimumab
Isatuximab
Isunakinra
Ixekizumab
Janus kinase
KEGG
KRAS
Lapatinib
Larotrectinib
Lazertinib
Lebrikizumab
Lenvatinib
Leridistim
Lestaurtinib
Leukemia
Levilimab
Loncastuximab tesirine
Lorlatinib
Lutikizumab
Lymphatic system
Lymphoma
MAb 1339
MEN1
MTOR inhibitor
Masitinib
MedlinePlus
Mepolizumab
Midostaurin
Milodistim
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobenakin
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody therapy
Mosunetuzumab
Moxetumomab pasudotox
Muplestim
Myeloid
NNC0114-0005
NNC0114-0006
Naxitamab
Necitumumab
Neratinib
Nilotinib
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Obinutuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Olokizumab
Oportuzumab monatox
Oprelvekin
Orelabrutinib
Osimertinib
PMID (identifier)
Pacritinib
Palbociclib
Panitumumab
Parsaclisib
Pascolizumab
Pazopanib
Pegaldesleukin
Pembrolizumab
Pemigatinib
Perakizumab
Pertuzumab
Pexidartinib
Pharmaceutical drug
Pharmacokinetics
Pi3K inhibitor
Pifonakin
Pirtobrutinib
Pitrakinra
Platelet-derived growth factor receptor
Polatuzumab vedotin
Ponatinib
Pralsetinib
Prescription drug
Proapoptotic
Prohibitin
Prolgolimab
Promegapoietin
Quizartinib
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Receptor modulator
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Remtolumab
Repotrectinib
Reslizumab
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilonacept
Ripretinib
Risankizumab
Rituximab
Rociletinib
Route of administration
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Sarilumab
Secukinumab
Selpercatinib
Selumetinib
Semaxanib
Serplulimab
Siltuximab
Sirolimus
Sirukumab
Sonidegib
Sorafenib
Sotorasib
Src (gene)
Sugemalimab
Sunitinib
T-cell lymphoma
TPI ASM8
Tadekinig
Tafasitamab
Talquetamab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Teceleukin
Teclistamab
Temsirolimus
Tepotinib
Tildrakizumab
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Tocilizumab
Toripalimab
Tositumomab
Tralokinumab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trilaciclib
Tucatinib
Tucotuzumab celmoleukin
Tyrosine kinase inhibitor
Unique Ingredient Identifier
Ustekinumab
VEGF receptors
Vandetanib
Vascular endothelial growth factor
Vascular endothelial growth factor A
Vemurafenib
Venetoclax
Vismodegib
Vunakizumab
YM-90709
Zanidatamab
Zanubrutinib
Zenocutuzumab
Zolbetuximab